US 12,281,140 B2
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
Guoqiang Wang, Belmont, MA (US); Yat Sun Or, Waltham, MA (US); Ruichao Shen, Belmont, MA (US); Jiang Long, Wayland, MA (US); Peng Dai, Auburndale, MA (US); Xuechao Xing, Wilmington, MA (US); and Jing He, Somerville, MA (US)
Assigned to Enanta Pharmaceuticals, Inc., Watertown, MA (US)
Filed by Enanta Pharmaceuticals, Inc., Watertown, MA (US)
Filed on May 4, 2023, as Appl. No. 18/143,166.
Application 18/143,166 is a continuation of application No. 17/186,447, filed on Feb. 26, 2021, granted, now 11,718,641.
Application 17/186,447 is a continuation of application No. 16/878,329, filed on May 19, 2020, granted, now 10,968,249, issued on Apr. 6, 2021.
Application 16/878,329 is a continuation of application No. 16/222,380, filed on Dec. 17, 2018, granted, now 10,696,713, issued on Jun. 30, 2020.
Application 16/222,380 is a continuation of application No. 14/951,989, filed on Nov. 25, 2015, granted, now 10,208,081, issued on Feb. 19, 2019.
Claims priority of provisional application 62/103,374, filed on Jan. 14, 2015.
Claims priority of provisional application 62/084,769, filed on Nov. 26, 2014.
Prior Publication US 2024/0140984 A1, May 2, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07J 41/00 (2006.01); C07J 43/00 (2006.01); C07J 51/00 (2006.01); C07J 9/00 (2006.01)
CPC C07J 41/0066 (2013.01) [C07J 41/0055 (2013.01); C07J 41/0088 (2013.01); C07J 43/003 (2013.01); C07J 43/006 (2013.01); C07J 9/005 (2013.01); C07J 41/0094 (2013.01); C07J 51/00 (2013.01)] 8 Claims
 
1. A pharmaceutical composition comprising a compound selected from the compounds below

OG Complex Work Unit Chemistry
or pharmaceutically acceptable salt thereof,
and a pharmaceutically acceptable carrier;
wherein said pharmaceutical composition is a solid dosage form suitable for oral administration.